Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $73 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $73.
August 04, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $73.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $73 price target indicates a positive outlook for Intra-Cellular Therapies. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100